



KNOW NOW. NO DOUBTS.

Annual Shareholders
Meeting
September 2015

Who are we?

TruScreen Limited specialises in the research, development and commercialisation of electro-light technologies for the '*real-time*' **identification of cancerous tissue**.

TruScreen is currently targeting the screening and treatment of cervical cancer but the TruScreen technology has the potential to be used to identify other cancers such as bowel, oral and pharyngeal cancers.

NB Interview With Professor Hacker



What is TruScreen?

The Only

- Real Time
- Proven and Certified
- Optical & Electrical
- Cervical Cancer
- Screening Device

In the World



Year's Highlights & Achievements

- Delivered all significant promises to investors
- Listed on NZAX November 12, 2014
- Pre Listing placement raised ≈ \$6m
- Chinese Food & Drug Administration (CFDA) registration in April 2015
- Reported revenues surpassed forecasts
- Devices have been fault free with no defects



Year's Highlights & Achievements (continued)

- Sensitivity of TruScreen has surpassed original certification & substantially surpassed PAP testing.
- Registration & Sales Distribution channels have been established in key & significant markets.
- Continuous Research & Development programs for improvement.
- Successfully completed Capital Raising in May/June 2015 >\$5m.
- Strong Balance Sheet - No Debt and Low Cash Burn.



The Big Picture

- **\$5 Billion** Worldwide market.
- **3rd** most prevalent cancer for women in the world
- 300,000 fatalities worldwide
- **88%** of these in **developing** countries
- High mortality linked to low screening incidence



Our Target Markets

No 1 focus is China

Other markets

- Latin America
- SE Asia
- Central Asia,
- Mid East,
- Eastern Europe,
- Russia,



NB Interview With Beijing SiWeiXianTai Technology Co

China

- Potentially the World's largest market - \$1billion p.a.
- 388 Million Women of Screening Age
- No Existing National Pap Program
- Increasing Government Focus on Women's Health
- Limited existing pathology infrastructure
- CFDA Approval Received 30 April, 2015



China (continued)

- Distributors contracted and key hospitals and experts engaged
- 100 Hospitals, 100,000 women aimed to be screened in China Doctors Association program
- 130,000 women aimed to be screened in Sinopec Shengli Oil Fields program
- 17 Event National Launch Program commenced July 2015



NB Interview With Professor Zhang

Regulatory Approvals to date

- China (CFDA),
- Europe (CE),
- Australia (TGA),
- New Zealand (WAND),
- Russia (RFDA),
- Mexico (COFERPRIS)

Note: These key registrations enable Sales & Distribution into several aligned & ancillary markets.

Interview with Tecnologico De Monterrey and Dr Lua




R & D Program

- Major physical product upgrade complete
 - Wireless
 - Wi Fi connectivity
 - No console
 - Updated optics and electronics
 - Increased specificity
- Due for Production Release in late 2015.
- Continuous development of software capabilities



R & D Program



R & D Program



Other Product Opportunities

- Ovarian Cancer
- Bowel Cancer
- Mouth, Tongue and Throat Cancers
- Melanoma detection
- STI's (Sexually Transmitted Infections)
- Veterinary applications

Interview with Dr Blakemore



Current Focus

- Global launch of new device
- Ramp up sales globally with a focus on China
- Fast track software development





THANK YOU